Reyvow is a Oral Tablet in the Human Prescription Drug category. It is labeled and distributed by Eli Lilly And Company. The primary component is Lasmiditan.
Product ID | 0002-4736_868fab51-8a3d-46a5-b6a6-9c1194a945c0 |
NDC | 0002-4736 |
Product Type | Human Prescription Drug |
Proprietary Name | Reyvow |
Generic Name | Lasmiditan |
Dosage Form | Tablet |
Route of Administration | ORAL |
Marketing Start Date | 2020-12-18 |
Marketing Category | NDA / NDA |
Application Number | NDA211280 |
Labeler Name | Eli Lilly and Company |
Substance Name | LASMIDITAN |
Active Ingredient Strength | 200 mg/1 |
DEA Schedule | CV |
NDC Exclude Flag | N |
Listing Certified Through | 2021-12-31 |
Marketing Start Date | 2020-12-18 |
NDC Exclude Flag | N |
Sample Package? | N |
NDC | Brand Name | Generic Name |
---|---|---|
0002-4312 | Reyvow | lasmiditan |
0002-4491 | Reyvow | lasmiditan |
0002-4736 | Reyvow | lasmiditan |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
![]() REYVOW 88035791 not registered Live/Pending |
Eli Lilly and Company 2018-07-12 |
![]() REYVOW 87446502 not registered Live/Pending |
Eli Lilly and Company 2017-05-11 |
![]() REYVOW 86926214 not registered Dead/Abandoned |
ELANCO US INC. 2016-03-02 |
![]() REYVOW 85685418 not registered Dead/Abandoned |
Eli Lilly and Company 2012-07-24 |
![]() REYVOW 85042374 not registered Dead/Abandoned |
Eli Lilly and Company 2010-05-19 |
![]() REYVOW 77141452 not registered Dead/Abandoned |
Eli Lilly and Company 2007-03-27 |